Revvity's AI-Fueled Life Sciences Recovery and Strategic China Divestiture
Strong Q2 beat and raised guidance highlight accelerating AI-driven demand, but software weakness and China exit temper the outlook.
PKI · Earnings Call · 2026-08-06
Q2 Beat and Raised Guidance
Revvity delivered a strong second quarter, with pro forma organic growth of 3% and adjusted EPS of $1.41, well above the high end of guidance. Management credited better-than-expected underlying performance, tax timing, and $16 million of tariff refunds. As Prahlad Singh noted, “These results reflect the continued strength and resilience of our Diagnostics franchise, the third consecutive quarter of improving conditions across our pharma and biotech end markets, growing customer demand for tools that enable AI-driven science and the continued momentum of our Signals software business.” — Prahlad Singh · 2026-08-06 The company raised its full-year organic growth outlook to 4-5% (from 3-4%) and adjusted EPS to $5.30-5.40 (up $0.10). The beat was broad-based, but the real story is the accelerating demand tied to AI-driven drug discovery. “We are now seeing tangible signs of a more constructive spending environment... a definitive and progressively larger increase in orders directly related to AI, reflecting demand from both traditional pharma and biotech customers as well as emerging demand from non-traditional customers.” — Prahlad Singh · 2026-08-06 This is not just hype; the company's flagship high-content screening instrument, Opera Phenix OptIQ, saw order velocity outpace production capacity.“Demand for our high-content screening instruments... remains extremely robust with continued double-digit growth year-over-year despite more difficult year ago comparisons.” — Prahlad Singh · 2026-08-06Life Sciences: Signs of a Turn
Life Sciences revenue declined 3% organically, but that was entirely due to a 20% drop in the Signals software business (expected comp headwind). Excluding software, pharma/biotech grew low single digits, and instruments showed renewed strength. Management highlighted a record backlog—the “strongest position in terms of backlog we've had in the past 3 to 4 years” — Prahlad Singh · 2026-08-06—as customers buy high-content screening systems and related reagents. This is a classic leading indicator for revenue acceleration in the second half. The AI theme extends across the portfolio. New software offerings such as Signals AI and the Anthropic connector are designed to close the "Lab-in-the-Loop" loop, further entrenching Revvity in the preclinical workflow. The company is positioning itself at the High performance computing intersection of biology and AI, even as the broader data center AI narrative plays out elsewhere. “Revvity's instruments and reagents generate the data. Signals One manages and structures it... allowing scientists to close that loop in ways that were simply not possible before.” — Prahlad Singh · 2026-08-06 The improving pharma/biotech environment is a macro tailwind. As Max Krakowiak noted, “It appears that our pharma and biotech customers are beginning to return to more normalized patterns, while increasing AI-related work is creating incremental demand, which did not exist in the past.” — Maxwell Krakowiak · 2026-08-06 This is not yet fully reflected in the guide; the new outlook already incorporates stronger instrumentation growth (mid-single-digit vs. low-single-digit previously), but does not assume a further acceleration in end markets.Diagnostics Strength and Strategic Focus
Diagnostics grew 11% organically, with reproductive health up mid-teens and immunodiagnostics ex-China up high single digits. The performance is particularly impressive as it continues despite global birth rate pressures. Management also announced a definitive agreement to divest the China immunodiagnostics business, a move that sharpens focus on higher-return markets. The deal is expected to close by end of 2027, and the company will report pro forma numbers excluding this business. Software remains the soft spot: “The decline in Life Sciences was driven by the approximately 20% decline in our Signals software business as we had expected due to contract timing and comps from a year ago.” — Maxwell Krakowiak · 2026-08-06 But with double-digit APV growth and a return to growth expected in the back half, the company is confident. The AI optimized servers analogy is apt: just as AI infrastructure spending is driving demand for compute, Revvity is seeing analogous pull from its instrument and software portfolio that enables AI-driven biological discovery.Cash generation was exceptional—117% conversion of adjusted net income—and the company is deleveraging after paying off a €500 million note. With a strong balance sheet and a clearer portfolio, Revvity enters the second half with momentum. The raised guidance reflects confidence, but the real long-term story is the company's pivot to being an indispensable partner in AI-driven science. From prior calls, this AI narrative has been building. As Prahlad said in February 2026, “Synthetica for me is not an AI. It's even more potentially important in the near term as it is in the longer term because what it does is it brings to action how drug discovery happens.” — Prahlad Singh, President and Chief Executive Officer · 2026-02-02 The consistency of this messaging, now backed by tangible order acceleration, elevates the credibility of the investment thesis.We are increasingly optimistic that not only is Revvity extremely well positioned to capitalize on the fundamental shift in how preclinical R&D is conducted, but also that we are currently only seeing the very initial stages of that transformation.